MOUNTAIN VIEW, Calif., Sept. 11 /PRNewswire/ -- Aviron (Nasdaq: AVIR)
today announced that Harry B. Greenberg, M.D. has been named senior vice
president, research and development and chief scientific officer.
Dr. Greenberg will be responsible for all of Aviron's research and
development programs, including those supporting FluMist(TM), an
investigational intranasal influenza vaccine, and other pipeline products,
including vaccines to prevent disease from cytomegalovirus, Epstein-Barr
virus, herpes simplex virus type 2, parainfluenza virus and respiratory
syncytial virus.
Dr. Greenberg has spent the past 17 years on the faculty of the Stanford
University School of Medicine, most recently as senior associate dean for
research and the Joseph D. Grant endowed professor of medicine. He also was
serving as associate chief of staff for research at the Veterans
Administration Palo Alto Health Care System. From 1999 until beginning his
assignment with Aviron, he served as chair of the Vaccines and Related
Biological Products Advisory Committee of the U.S. Food and Drug
Administration (FDA). During the past 30 years, Dr. Greenberg has conducted
significant research in the fields of virology and immunology with the
Palo Alto Veterans Administration and the National Institute of Allergy and
Infectious Disease. Dr. Greenberg earned a bachelor's degree from Dartmouth
College and his M.D. from Columbia College of Physicians and Surgeons.
Dr. Greenberg has authored or co-authored more than 250 papers on topics
including vaccines, immunology and gastroenterology. He has also written
chapters for more than 40 medical textbooks and served on the editorial boards
of several major scientific journals. Dr. Greenberg has served as a member of
Aviron's scientific advisory board since the company's founding in 1992.
"Harry Greenberg is acknowledged as one of the world's leading authorities
on vaccines. His addition to our management team greatly strengthens Aviron's
scientific capabilities as we continue to move our vaccine programs through
the research and development pipeline towards commercialization, and as we
prepare for a fourth quarter submission of a Biologics License Application for
FluMist(TM) to the FDA," said C. Boyd Clarke, Aviron president and chief
executive officer.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Actual results may differ materially from the forward-looking statements
contained in this release. Factors that could cause actual results to differ
include, but are not limited to, failure to validate the manufacturing
process, facilities or equipment for the company's nasal influenza vaccine,
and the assessment by regulatory agencies that the company's future license
applications for its nasal influenza vaccine are incomplete or inadequate to
approve the product for marketing to one or more target populations.
Additional information concerning factors that could cause such a difference
is contained in Aviron's SEC filings, including its S-3 Registration Statement
and Annual Report on Form 10-K for the year ended December 31, 1999.
To receive an index and copies of recent press releases, call Aviron's
News-On-Call toll-free fax service, 800-758-5804, extension 114000.
Additional information about the company can be located at
http://www.aviron.com .
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
Media, John Bluth of Aviron, 650-919-3716, or
Claudette Hibbert of Fleishman-Hillard, 212-453-2000, for Aviron;
or investors, John Bluth, 650-919-3716, or Fred Kurland,
650-919-6666, both of Aviron
|
